Biogen Inc. and Reata Pharmaceuticals, Inc. have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.Reata has made advancements developing therapeutics that regulate…
Source: www.labiotech.eu – Read more
Attackers test the limits of railway cybersecurity
Railway systems are the lifeblood of many economies, supporting everything from daily passenger transport to military and industrial operations, so the question arises: how secure
